Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
15°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gracell Biotechnologies Inc ADR
(NQ:
GRCL
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gracell Biotechnologies Inc ADR
< Previous
1
2
3
4
5
Next >
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
January 05, 2024
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies
December 26, 2023
Via
Benzinga
A Preview Of Gracell Biotechnologies's Earnings
November 10, 2023
Via
Benzinga
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
December 31, 2023
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program....
Via
Talk Markets
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Investor Sentiment Improves; Dow Jumps Over 150 Points
December 27, 2023
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
December 26, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Latest Analyst Ratings for Gracell Biotechnologies
October 19, 2023
Via
Benzinga
4 Analysts Have This to Say About Gracell Biotechnologies
August 30, 2023
Via
Benzinga
Preview: Gracell Biotechnologies's Earnings
August 11, 2023
Via
Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 26, 2023
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 26, 2023
Via
Benzinga
Crude Oil Rises Over 3%; US Home Prices Increase In October
December 26, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 26, 2023
Via
Benzinga
Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket
December 26, 2023
Shares of Sentage Holdings Inc. (NASDAQ: SNTG) shares moved lower in pre-market trading following results for the six months ended June 30, 2023.
Via
Benzinga
US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs
December 26, 2023
Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy.
Via
Benzinga
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
December 26, 2023
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio.
Via
Benzinga
Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
December 26, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Bitfarms And Other Big Stocks Moving Lower On Friday
November 24, 2023
U.S. stocks traded mixed, with the Dow Jones gaining around 90 points on Friday. Shares of Bitfarms Ltd. (NASDAQ: BITF) shares fell sharply during Friday’s session after the company announced a C$60...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
October 19, 2023
Via
Benzinga
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
September 30, 2023
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
August 12, 2023
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.